ArticleFrontiers in psychiatry2025
Medication adherence in obsessive-compulsive disorders and evaluation of effective adherence support strategies.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Medication adherence is a critical component in the treatment of psychiatric conditions such as obsessive-compulsive disorder (OCD). Poor adherence is associated with an increased risk of relapse, subsequent (re)hospitalization, and prolonged remission, which ultimately leads to a worse prognosis. This study aimed to assess medication adherence over time in individuals with OCD, identify predictors, and gather patient-reported strategies to maintain adherence. Methods: This study surveyed Results: The participants exhibited mild impairments in various aspects of functioning despite relatively functional daily lives. Most were prescribed selective serotonin reuptake inhibitors (SSRIs), with a subset receiving combination therapy for treatment-resistant cases. Medication adherence was classified into three categories: 24.4% of the participants were good adherers, 62.2% were partially adherent, and 13.4% were non-adherent. Therapeutic drug monitoring (TDM) indicated that 84.6% of the participants had drug levels within the therapeutic range. Concerns about side effects and doubts regarding the efficacy of the medication were commonly reported, which might contribute to suboptimal adherence. However, no significant associations were found between adherence and sociodemographic or clinical variables, which suggested the need for a more comprehensive approach considering psychosocial factors. Behavioral strategies for maintaining adherence (e.g., incorporating medication into daily routines) were preferred and rated as helpful, while invasive monitoring methods were largely rejected. Discussion: This study highlights the importance of a multifaceted approach to improving medication adherence in individuals with OCD. While SSRIs remain the primary pharmacological treatment, a significant portion of patients still struggle with adherence. Although TDM provides valuable insights into drug levels, it may not fully capture adherence behavior due to metabolic and behavioral variability. Addressing patient concerns about side effects and medication efficacy, alongside implementing behavioral strategies that integrate medication into daily routines, may improve adherence and enhance treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.